POL 6014

Drug Profile

POL 6014

Alternative Names: POL6014

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polyphor
  • Developer Polyphor; Santhera Pharmaceuticals
  • Class Macrocyclic compounds; Peptides; Small molecules
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cystic fibrosis
  • Phase I Alpha 1-antitrypsin deficiency; Bronchiectasis
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 18 May 2018 Pharmacodynamics data from a preclinical study in Cystic fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 15 Feb 2018 Polyphor plans a multiple ascending dose clinical trial for Cystic fibrosis in European Union in the second half of 2018
  • 15 Feb 2018 POL 6014 licensed to Santhera worldwide (9233504; 9233668)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top